Inhibition of receptor‐binding domain—ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS‐CoV‐2 vaccines

• Published in: Journal of medical virology Vol. 94; no. 3; pp. 1217 - 1223
• Main Authors: Silva, Valéria O., Yamashiro, Rosemeire, Ahagon, Cintia M., Campos, Ivana B., de Oliveira, Isabela P., de Oliveira, Elaine L., López‐Lopes, Giselle I. S., Matsuda, Elaine M., Castejon, Marcia J., de Macedo Brígido, Luís F.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2022; John Wiley and Sons Inc
• Subjects: ACE2; Angiotensin; Angiotensin-Converting Enzyme 2; Angiotensins; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Antibody response; Binding; ChAdOx1 nCoV-19; Clinical trials; Conversion; Coronaviruses; COVID-19 - prevention & control; COVID-19 Vaccines; COVID‐19; Domains; Enzymes; Evaluation; Humans; Infections; Laboratories; Neutralization; Receptors; Receptor‐Binding Domain; Respiratory diseases; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Short Communication; Spike Glycoprotein, Coronavirus; Vaccine; Vaccine efficacy; Vaccines; Viral diseases; Viral Neutralization; Virology; COVID-19; Receptor-Binding Domain; Antibodies; SARS-CoV-2; Vaccine; Viral Neutralization

Practical laboratory proxies that correlate to vaccine efficacy may facilitate trials, identify nonresponders, and inform about boosting strategies. Among clinical and laboratory markers, assays that evaluate antibodies that inhibit receptor‐binding domain (RBD) ligation to angiotensin‐converting en...